- Home
- MIRM
as 02-21-2025 4:00pm EST
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Upcoming Earnings Alert:
Get ready for potential market movements as Mirum Pharmaceuticals Inc. MIRM prepares to release earnings report on 26 Feb 2025.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 2.5B | IPO Year: | 2019 |
| Target Price: | $57.00 | AVG Volume (30 days): | 504.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.14 - $54.23 | Next Earning Date: | 02-26-2025 |
| Revenue: | $307,028,000 | Revenue Growth: | 112.14% |
| Revenue Growth (this year): | 83.04% | Revenue Growth (next year): | 27.22% |
Stock Insider Trading Activity of Mirum Pharmaceuticals Inc. (MIRM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Radovich Peter | MIRM | PRESIDENT AND COO | Feb 3 '25 | Sell | $48.22 | 2,627 | $126,680.77 | 26,961 | |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Feb 3 '25 | Sell | $48.22 | 9,102 | $438,921.19 | 115,920 | |
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Jan 31 '25 | Sell | $48.22 | 1,064 | $51,308.74 | 4,232 | |
| Radovich Peter | MIRM | PRESIDENT AND COO | Jan 23 '25 | Sell | $47.92 | 3,177 | $152,256.14 | 26,961 | |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Jan 23 '25 | Sell | $47.92 | 6,837 | $327,658.44 | 115,920 | |
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Jan 23 '25 | Sell | $47.92 | 902 | $43,227.81 | 4,232 | |
| Quan Joanne | MIRM | CHIEF MEDICAL OFFICER | Jan 16 '25 | Sell | $45.86 | 6,969 | $319,598.34 | 5,649 | |
| Radovich Peter | MIRM | PRESIDENT AND COO | Jan 7 '25 | Sell | $42.82 | 1,998 | $85,544.97 | 26,961 | |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Jan 7 '25 | Sell | $42.82 | 7,489 | $320,643.78 | 115,920 | |
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Jan 6 '25 | Sell | $42.82 | 750 | $32,111.48 | 4,232 |
Latest Mirum Pharmaceuticals Inc. News
MIRM Breaking Stock News: Dive into MIRM Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025
Simply Wall St.
3 days ago
High Growth Tech Stocks in United States to Watch
Business Wire
11 days ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
25 days ago
Mirum Pharmaceuticals Insider Sold Shares Worth $327,658, According to a Recent SEC Filing
Zacks
a month ago
Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock?
MT Newswires
a month ago
Mirum Pharmaceuticals Insider Sold Shares Worth $319,598, According to a Recent SEC Filing
Zacks
a month ago
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results
Simply Wall St.
a month ago
Exploring Three High Growth Tech Stocks in the United States
Compare MIRM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIRM Mirum Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.